Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Anticholinergic smooth muscle relaxant with antimuscarinic action used to relieve spasticity, inflammation, pain, and incontinence of the urinary tract. Oral administration in 3 doses per day.
At the time of the last update, we found no published data on its excretion in breast milk.
Its pharmacokinetic data (moderately high molecular weight and distribution volume and high percentage of plasma protein binding) (Guay 2003, Bertoli 1976) make it unlikely to pass into breast milk in clinically significant amounts.
The antimuscarinic effect may reduce prolactin production (Masala 1982, De Martino 1980). Once lactation is established, milk production depends more on stimulation and regular emptying of the breast than on prolactin concentration.
Side effects are very rare and occasional use would pose a low risk during breastfeeding.
Monitor milk production and anticholinergic symptoms in the infant: irritability, nausea or constipation.
Until more data on this drug in relation to breastfeeding is published, alternatives with a known pharmacokinetic profile that is safer for breastfeeding (greater protein binding, shorter half-life and lower oral bioavailability) may be preferable, especially during the neonatal period and in cases of prematurity.